BRAF V600E mutation-specific antibody: A review

Seminars in Diagnostic Pathology

Volumn 32, Issue 5, 2015, Pages 400-408

  Ritterhouse, Lauren L ^a   Barletta, Justine A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRAF V600E; Colorectal carcinoma; Immunohistochemistry; Melanoma; Thyroid carcinoma

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VE1; UNCLASSIFIED DRUG; VALINE; ANTIBODY; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BRAF GENE; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; THYROID CARCINOMA; ANTIBODY SPECIFICITY; CARCINOMA; COLORECTAL TUMOR; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MOLECULAR DIAGNOSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; SKIN TUMOR; THYROID TUMOR;

ANTIBODIES; ANTIBODY SPECIFICITY; BIOMARKERS, TUMOR; CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; THYROID NEOPLASMS;

EID: 84940447406     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.02.010     Document Type: Article

References (93)

1. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
2. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
3. Rajagopalan H., Bardelli A., Lengauer C., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418(6901):934.
4. Chan T.L., Zhao W., Leung S.Y., et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003, 63(16):4878-4881.
5. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63(7):1454-1457.
6. Singer G., Oldt R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95(6):484-486.
7. Badalian-Very G., Vergilio J.A., Degar B.A., et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010, 116(11):1919-1923.
8. Dias-Santagata D., Lam Q., Vernovsky K., et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011, 6(3):e17948.
9. Schindler G., Capper D., Meyer J., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121(3):397-405.
10. Tiacci E., Trifonov V., Schiavoni G., et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364(24):2305-2315.
11. Kurppa K.J., Catón J., Morgan P.R., et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014, 232(5):492-498.
12. Choueiri T.K., Cheville J., Palescandolo E., et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012, 62(5):917-922.
13. Ilie M., Long E., Hofman V., et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013, 24(3):742-748.
14. Goeppert B., Frauenschuh L., Renner M., et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 2014, 27(7):1028-1034.
15. Weber A., Langhanki L., Sommerer F., et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003, 22(30):4757-4759.
16. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47(10):853-859.
17. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471(7339):467-472.
18. Ihle M.A., Fassunke J., König K., et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014, 14(13):13.
19. Anderson S., Bloom K.J., Vallera D.U., et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11):1385-1391.
20. Andersen J.B., Spee B., Blechacz B.R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012, 142(4):1021-1031. [e1015].
21. Capper D., Preusser M., Habel A., et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011, 122(1):11-19.
22. Boursault L., Haddad V., Vergier B., et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One 2013, 8(8):e70826.
23. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353(20):2135-2147.
24. Bauer J., Buttner P., Murali R., et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011, 24(2):345-351.
25. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29(10):1239-1246.
26. Shinozaki M., Fujimoto A., Morton D.L., et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004, 10(5):1753-1757.
27. Kim G., McKee A.E., Ning Y.M., et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. Clin Cancer Res 2014, 20(19):4994-5000.
28. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
29. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365.
30. Long G.V., Stroyakovskiy D., Gogas H., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 371(20):1877-1888.
31. Busam K.J., Hedvat C., Pulitzer M., et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013, 37(3):413-420.
32. Chen Q., Xia C., Deng Y., et al. Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. Tumour Biol 2014, 35(6):5727-5733.
33. Colomba E., Hélias-Rodzewicz Z., Von Deimling A., et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15(1):94-100.
34. Feller J.K., Yang S., Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol 2013, 26(3):414-420.
35. Hofman V., Ilie M., Long-Mira E., et al. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol 2013, 133(5):1378-1381.
36. Lade-Keller J., Kristensen L.S., Riber-Hansen R., et al. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?. J Clin Pathol 2013, 66(8):723-725.
37. Long G.V., Wilmott J.S., Capper D., et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013, 37(1):61-65.
38. Pearlstein M.V., Zedek D.C., Ollila D.W., et al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol 2014, 41(9):724-732.
39. Routhier C.A., Mochel M.C., Lynch K., et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013, 44(11):2563-2570.
40. Skorokhod A., Capper D., von Deimling A., et al. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012, 67(3):488-491.
41. Heinzerling L., Kühnapfel S., Meckbach D., et al. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer 2013, 108(10):2164-2171.
42. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30(2):216-222.
43. Jung C.K., Little M.P., Lubin J.H., et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014, 99(2):E276-E285.
44. Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011, 135(5):569-577.
45. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88(11):5399-5404.
46. Ghossein R.A., Katabi N., Fagin J.A. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 2013, 98(8):E1414-E1421.
47. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90(12):6373-6379.
48. Howell G.M., Nikiforova M.N., Carty S.E., et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013, 20(1):47-52.
49. Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381(9871):1058-1069.
50. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010, 321(1):86-93.
51. Xing M. BRAF V600E mutation and papillary thyroid cancer. J Am Med Assoc 2013, 310(5):535.
52. Howitt B.E., Jia Y., Sholl L.M., Barletta J.A., et al. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 2013, 23(10):1256-1262.
53. Rivera M., Ricarte-Filho J., Patel S., et al. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol 2010, 41(2):172-180.
54. Kim K.B., Cabanillas M.E., Lazar A.J., et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013, 23(10):1277-1283.
55. Rosove M.H., Peddi P.F., Glaspy J.A. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013, 368(7):684-685.
56. Bullock M., O'Neill C., Chou A., et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012, 19(6):779-784.
57. Crescenzi A., Guidobaldi L., Nasrollah N., et al. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers. Horm Metab Res 2014, 46(5):370-374.
58. Fisher K.E., Neill S.G., Ehsani L., et al. Immunohistochemical investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. Appl Immunohistochem Mol Morphol 2014, 22(8):562-567.
59. Ilie M.I., Lassalle S., Long-Mira E., et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014, 24(5):858-866.
60. Kim Y.H., Choi S.E., Yoon S.O., et al. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Hum Pathol 2014, 45(7):1483-1488.
61. Koperek O., Kornauth C., Capper D., et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36(6):844-850.
62. McKelvie P.A., Chan F., Yu Y., et al. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology 2013, 45(7):637-644.
63. Zagzag J., Pollack A., Dultz L., et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery 2013, 154(6):1199-1204. [discussion 1204-1205].
64. Zimmermann A.K., Camenisch U., Rechsteiner M.P., et al. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol 2014, 122(1):48-58.
65. Day F., Muranyi A., Singh S., et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2014, PMID: 24859797, [in press].
66. Tran B., Kopetz S., Tie J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117(20):4623-4632.
67. Huang C.S., Farraye F.A., Yang S., et al. The clinical significance of serrated polyps. Am J Gastroenterol 2011, 106(2):229-240. [quiz 241].
68. Ogino S., Nosho K., Kirkner G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58(1):90-96.
69. Gibson J., Lacy J., Matloff E., Robert M. Microsatellite instability testing in colorectal carcinoma: a practical guide. Clin Gastroenterol Hepatol 2014, 12(2):171-176. [e1].
70. Lin C.C., Lin J.K., Lin T.C., et al. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 2014, 110(4):451-457.
71. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361(1):98-99.
72. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
73. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
74. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483(7387):100-103.
75. Adackapara C.A., Sholl L.M., Barletta J.A., et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013, 63(2):187-193.
76. Affolter K., Samowitz W., Tripp S., et al. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer 2013, 52(8):748-752.
77. Bledsoe J.R., Kamionek M., Mino-Kenudson M. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. Am J Surg Pathol 2014, 38(10):1418-1428.
78. Capper D., Voigt A., Bozukova G., et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013, 133(7):1624-1630.
79. Ilie M.I., Long-Mira E., Hofman V., et al. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Pathology 2014, 46(4):311-315.
80. Kuan S.F., Navina S., Cressman K.L., et al. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol 2014, 45(3):464-472.
81. Lasota J., Kowalik A., Wasag B., et al. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Am J Surg Pathol 2014, 38(9):1235-1241.
82. Rössle M., Sigg M., Rüschoff J.H., et al. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch 2013, 463(5):623-631.
83. Sajanti S., Sirniö P., Väyrynen J.P., et al. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch 2014, 464(6):637-643.
84. Sinicrope F.A., Smyrk T.C., Tougeron D., et al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer 2013, 119(15):2765-2770.
85. Thiel A., Heinonen M., Kantonen J., et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 2013, 463(5):613-621.
86. Toon C.W., Walsh M.D., Chou A., et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013, 37(10):1592-1602.
87. Dougherty M.J., Santi M., Brose M.S., et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010, 12(7):621-630.
88. Brastianos P.K., Taylor-Weiner A., Manley P.E., et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014, 46(2):161-165.
89. Ida C.M., Vrana J.A., Rodriguez F.J., et al. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun 2013, 1(1):20.
90. Andrulis M., Penzel R., Weichert W., et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012, 36(12):1796-1800.
91. Brown N.A., Rolland D.C., McHugh J.B., et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 2014, 20(21):5517-5526. [in press].
92. Pinto A., Signoretti S., Hirsch M.S., Barletta J.A. Immunohistochemical staining for braf v600e supports the diagnosis of metanephric adenoma. Histopathology 2014, http://dx.doi.org/10.1111/his.12509, [in press].
93. Bösmüller H., Fischer A., Pham D.L., et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013, 44(3):329-335.